| (210) | Number of the EPO application | 18803349 |
| (220) | Filing date of the EPO application | 2018.11.05 |
| (80) | EPO patent specification publication (B) | EPB nr. 01/2023, 2023.01.04 |
| (110) | EPO patent number | 3707159 |
| (21) | Number of the application | e 2020 0936 |
| (71) | Name(s) of applicant(s), code of the country | IMMATICS BIOTECHNOLOGIES GMBH, DE; |
| (72) | Name(s) of inventor(s), code of the country | UNVERDORBEN Felix, DE;
BUNK Sebastian, DE;
HOFMANN Martin, DE;
HUTT Meike, DE;
MAURER Dominik, DE;
ALTEN Leonie, DE;
WAGNER Claudia, DE; |
| (73) | Name(s) of owner(s), code of the country | IMMATICS BIOTECHNOLOGIES GMBH, DE; |
| (54) | Title of the invention | NOVEL ENGINEERED T CELL RECEPTORS AND IMMUNE THERAPY USING THE SAME |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | A61K 39/00 (2006.01.01); A61P 35/00 (2006.01.01); C07K 16/18 (2006.01.01); C07K 14/725 (2006.01.01); C07K 14/78 (2006.01.01); C07K 16/28 (2006.01.01); C07K 16/30 (2006.01.01); C12N 5/0783 (2010.01.01); C12N 15/62 (2006.01.01) |
| (19) | Country | DE |
| (41) | Date of publication of the application | 2020.10.31 |
| (30) | Priority | 102017125888, 2017.11.06, DE; 201762582202 P, 2017.11.06, US |
| (86) | International application | PCT/EP2018/080176, 2018.11.05 |
| (87) | International publication | WO 2019/086665, 2019.05.09 |